David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I think SRRK stock could be a Buy.

Scholar Rock shares launched 362% to 34.28. That put shares at their highest point since November 2021. The news also buoyed shares of Biohaven, which is working on a similar treatment option for ...

Scholar Rock also granted the underwriters of the offering a 30-day option to purchase up to an additional 1,861,314 shares of common stock at the offering price. For perspective, ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...

Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.

Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock’s Board of Directors as an independent director.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases ...

Scholar Rock Holding focuses on the discovery of drugs for treating illnesses, in which signaling by protein growth factors is important. SRRK tested a total of 58 patients in Phase 2.

CAMBRIDGE, Mass., February 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...